

examination purposes. Applicant further requests reconsideration of the restriction requirement.

The Examiner has required restriction to one of fifteen (I-XV) groupings. Applicant traverses the restriction requirement and respectfully points out that the restriction is improper, at least with respect to the subject matter of claims 4-6. The two groupings V and VI, directed to the subject matter of claims 4-6, do not collectively include the full scope of original claims 4-6. Specifically, neither group V nor group VI includes embodiments where A, B, and C are each CR. Embodiments where A, B, and C are each CR are clearly encompassed in the genus of original claims 4-6 and described, for example, on page 8 of the specification (see formula IId). Thus, embodiments where A, B, and C are each CR are improperly excluded from restriction groups I-XV defined in the Office Action.


For a restriction requirement to be valid, the Examiner must establish the following two criteria: (1) the existence of independent and distinct inventions, (35 U.S.C. 121); and (2) that the search and examination of the entire application cannot be made without serious burden (M.P.E.P. 803). The Examiner fails to show that at least the second requirement has been met. For example, the Examiner fails to show that embodiments of claims 4-6 where A, B, and C are each CR would present a serious burden on the Examiner if searched in conjunction with any of the fifteen named restriction groups. Applicant respectfully asserts that there would not be a serious burden on the Examiner to search such compounds in addition to the subject matter of the other restriction groups, especially Groups V and VI, because the core structures are substantially similar. For example, embodiments of claims 4-6 where A, B, and C are each CR differ by only one atom in the core structure from compounds of Group V.

In view of the above discussion, Applicant respectfully requests that the restriction requirement be reconsidered such that Group V further includes embodiments where A, B, and C are each CR.

In view of the foregoing, Applicant submits that the claims as amended are in condition for allowance, and an early Office Action to that effect is earnestly solicited.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "**Version with markings to show changes made.**"

Respectfully submitted,



Christine A. Goddard, Ph.D.
Registration No. 46,731

Date: *June 14, 2002*
Bristol-Myers Squibb Company
Experimental Station, E353/133
Route 141 and Henry Clay Road
Wilmington, DE 19880
(302) 467-5263
(302) 467-6701 (fax)



COPY OF PAPERS
ORIGINALLY FILED

DOCKET NO.: PH-7345-A

PATENT

VERSION WITH MARKING TO SHOW CHANGES MADE

In the claims:

Claims 1-3 and 7-18 have been canceled.

Claim 6 had been amended as follows.

RECEIVED

JUN 28 2002

TECH CENTER 1600/2900

6. (amended once) The method of claim [14] 5 wherein the disorder is stroke.